Outcome of patients with previous coronary artery bypass grafting and severe calcific aortic stenosis receiving transfemoral transcatheter aortic valve replacement.
Aged
Aged, 80 and over
Aortic Valve
/ diagnostic imaging
Aortic Valve Stenosis
/ diagnostic imaging
Calcinosis
/ diagnostic imaging
Catheterization, Peripheral
/ adverse effects
Coronary Artery Bypass
/ adverse effects
Female
Femoral Artery
Humans
Male
Punctures
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Time Factors
Transcatheter Aortic Valve Replacement
/ adverse effects
Treatment Outcome
CABG
TAVI
TAVR
aortic stenosis
coronary artery disease
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
12
08
2019
revised:
11
09
2019
accepted:
17
09
2019
pubmed:
13
11
2019
medline:
3
2
2021
entrez:
13
11
2019
Statut:
ppublish
Résumé
To evaluate the impact of previous coronary artery bypass grafting (CABG) on early safety at 30 days and 1-year mortality in patients receiving transcatheter aortic valve replacement (TAVR). The use of TAVR in patients with previous CABG suffering from severe aortic stenosis has increased in the last years. Consecutive TAVR patients were stratified according to previous CABG versus no previous cardiac surgery (control). All-cause 1-year mortality and early safety at 30 days were evaluated. In the unmatched cohort and compared to control (n = 2,364), CABG (n = 260) were younger, more often male and suffered more often from comorbidities leading to an increased STS-score (p < .001). The rate of early safety events at 30 days was comparable between CABG and control (21.2% vs. 24.6%, p = .22) with a higher mortality in CABG (9.6% vs. 5.3%, p = .005). All-cause 1-year mortality was higher in CABG compared to controls (HR 1.51 [95%-CI 1.15-1.97], p = .003). Applying Cox regression analysis, both 30-day (HR 1.57 [95%-CI 0.97-2.53], p = .067) and all-cause 1-year mortality (HR 1.24 [95%-CI 0.91-1.70], p = .174) were not significantly different between groups. After propensity-score matching, the rate of early safety events at 30 days was lower in CABG compared to controls (21.6% vs. 31.7%, p = .02). Thirty-day (9.1% vs. 7.7%, p = .596) and all-cause 1-year mortality (24.0% vs. 23.1%, p = .520, HR 1.14 [95%-CI 0.77-1.69], p = .520) were not different between groups. In patients receiving TAVR, previous CABG was not associated with an increase in periprocedural complications and all-cause 1-year mortality when adjusted for other comorbidities.
Sections du résumé
OBJECTIVES
To evaluate the impact of previous coronary artery bypass grafting (CABG) on early safety at 30 days and 1-year mortality in patients receiving transcatheter aortic valve replacement (TAVR).
BACKGROUND
The use of TAVR in patients with previous CABG suffering from severe aortic stenosis has increased in the last years.
METHODS
Consecutive TAVR patients were stratified according to previous CABG versus no previous cardiac surgery (control). All-cause 1-year mortality and early safety at 30 days were evaluated.
RESULTS
In the unmatched cohort and compared to control (n = 2,364), CABG (n = 260) were younger, more often male and suffered more often from comorbidities leading to an increased STS-score (p < .001). The rate of early safety events at 30 days was comparable between CABG and control (21.2% vs. 24.6%, p = .22) with a higher mortality in CABG (9.6% vs. 5.3%, p = .005). All-cause 1-year mortality was higher in CABG compared to controls (HR 1.51 [95%-CI 1.15-1.97], p = .003). Applying Cox regression analysis, both 30-day (HR 1.57 [95%-CI 0.97-2.53], p = .067) and all-cause 1-year mortality (HR 1.24 [95%-CI 0.91-1.70], p = .174) were not significantly different between groups. After propensity-score matching, the rate of early safety events at 30 days was lower in CABG compared to controls (21.6% vs. 31.7%, p = .02). Thirty-day (9.1% vs. 7.7%, p = .596) and all-cause 1-year mortality (24.0% vs. 23.1%, p = .520, HR 1.14 [95%-CI 0.77-1.69], p = .520) were not different between groups.
CONCLUSION
In patients receiving TAVR, previous CABG was not associated with an increase in periprocedural complications and all-cause 1-year mortality when adjusted for other comorbidities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E196-E203Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Matsumoto Y, Adams V, Walther C, et al. Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair. Eur Heart J. 2009;30:346-355.
Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, Linke A. Regular exercise training prevents aortic valve disease in low-density lipoprotein-receptor-deficient mice. Circulation. 2010;121:759-767.
Schlotter F, Matsumoto Y, Mangner N, Schuler G, Linke A, Adams V. Regular exercise or changing diet does not influence aortic valve disease progression in LDLR deficient mice. PLoS One. 2012;7:e37298.
Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-1798.
Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705-1715.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Fighali SF, Avendano A, Elayda MA, et al. Early and late mortality of patients undergoing aortic valve replacement after previous coronary artery bypass graft surgery. Circulation. 1995;92:II163-II168.
Odell JA, Mullany CJ, Schaff HV, Orszulak TA, Daly RC, Morris JJ. Aortic valve replacement after previous coronary artery bypass grafting. Ann Thorac Surg. 1996;62:1424-1430.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.
Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438-1454.
Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816-822.
O'Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2 - isolated valve surgery. Ann Thorac Surg. 2009;88:S23-S42.
Reinohl J, Kaier K, Reinecke H, et al. Transcatheter aortic valve replacement: the new standard in patients with previous coronary bypass grafting? JACC Cardiovasc Interv. 2016;9:2137-2143.
Gupta T, Khera S, Kolte D, et al. Transcatheter versus surgical aortic valve replacement in patients with prior coronary artery bypass grafting: trends in utilization and propensity-matched analysis of in-hospital outcomes. Circ Cardiovasc Interv. 2018;11:e006179.
Leontyev S, Borger MA, Davierwala P, et al. Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg. 2011;91:1120-1126.
Lytle BW, Cosgrove DM, Taylor PC, et al. Reoperations for valve surgery: perioperative mortality and determinants of risk for 1,000 patients, 1958-1984. Ann Thorac Surg. 1986;42:632.
Byrne JG, Karavas AN, Filsoufi F, et al. Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. Ann Thorac Surg. 2002;73:779-784.
Castellant P, Didier R, Bezon E, et al. Comparison of outcome of Transcatheter aortic valve implantation with versus without previous coronary artery bypass grafting (from the France 2 registry). Am J Cardiol. 2015;116:420-425.
Reardon MJ, Heijmen RH, Van Mieghem NM, et al. Comparison of outcomes after Transcatheter vs surgical aortic valve replacement among patients at intermediate operative risk with a history of coronary artery bypass graft surgery: a post hoc analysis of the SURTAVI randomized clinical trial. JAMA Cardiol. 2019;4(8):810-814.
Conte JV, Gleason TG, Resar JR, et al. Transcatheter or surgical aortic valve replacement in patients with prior coronary artery bypass grafting. Ann Thorac Surg. 2016;101:72-79.
Nguyen TC, Babaliaros VC, Razavi SA, et al. Transcatheter aortic valve replacement has improved short-term but similar midterm outcomes in isolated aortic valve replacement after prior coronary artery bypass grafting. Ann Thorac Surg. 2014;98:1316-1324.
Stortecky S, Brinks H, Wenaweser P, et al. Transcatheter aortic valve implantation or surgical aortic valve replacement as redo procedure after prior coronary artery bypass grafting. Ann Thorac Surg. 2011;92:1324-1330.
Greason KL, Mathew V, Suri RM, et al. Transcatheter versus surgical aortic valve replacement in patients with prior coronary artery bypass graft operation: a PARTNER trial subgroup analysis. Ann Thorac Surg. 2014;98:1-7.
Gasior T, Mangner N, Bijoch J, Wojakowski W. Cerebral embolic protection systems for transcatheter aortic valve replacement. J Interv Cardiol. 2018;31:891-898.